vaccin
confer
immun
protect
infecti
agent
diverg
arm
adapt
immun
respons
elabor
antibodi
humor
immun
system
highli
effect
neutral
mani
bacteria
virus
fungi
parasit
cellmedi
immun
respons
also
play
major
role
contain
infecti
agent
well
elimin
pathogen
cell
lymphocyt
compris
divers
set
cell
function
activ
depend
helper
cell
elabor
varieti
cytokin
stimul
b
cell
produc
antibodi
modul
induct
expans
cytotox
lymphocyt
ctl
ctl
recogn
process
antigen
combin
major
histocompat
complex
mhc
molecul
releas
cytokin
influenc
pathogen
replic
well
lyse
infect
cell
addit
tregulatori
cell
induc
part
immun
respons
play
neg
role
clearanc
chronic
infecti
agent
prevent
clearanc
pathogen
cell
humor
cellular
immun
elicit
vaccin
effector
function
inactiv
pathogen
differ
way
box
although
humor
immun
respons
well
known
confer
protect
role
ctl
protect
immun
viral
infect
recogn
recent
function
specif
ctl
provid
foundat
understand
mhc
restrict
import
protect
viral
infect
cellular
immun
respons
help
control
infecti
diseas
concert
antibodi
respons
difficult
gener
neutral
antibodi
patient
aid
malaria
hepat
c
viru
tuberculosi
humor
immun
readili
induc
protein
antigen
prepar
inactiv
virus
togeth
appropri
adjuv
genebas
vaccin
engin
nonvir
rnaor
dnabas
system
viral
recombin
system
express
foreign
antigen
deliv
host
appear
particularli
effect
induc
tcell
respons
time
genebas
vaccin
induc
humor
immun
respons
use
specif
vector
specif
primeboost
combin
enhanc
deliveri
formul
varieti
vector
nonvir
viral
develop
purpos
fig
studi
focu
enter
clinic
review
major
convent
adjuv
previous
use
vaccin
develop
affect
humor
immun
enhanc
antibodi
respons
without
induc
cellular
immun
contrast
genebas
vaccin
vector
stimul
humor
cellular
immun
thu
provid
greater
select
pressur
infecti
agent
chapter
major
genebas
vaccin
progress
clinic
trial
discuss
togeth
advantag
disadvantag
individu
vector
influenc
differ
effector
arm
immun
system
although
consider
experi
inactiv
virus
proteinbas
vaccin
less
experi
genebas
vaccin
vector
recent
develop
abil
induc
humor
cellular
immun
safeti
mode
antigen
present
attract
featur
must
balanc
limit
knowledg
develop
genebas
vector
immun
david
b
weiner
gari
j
nabel
clinic
efficaci
product
methodolog
concern
antivector
immun
box
howev
grow
clinic
experi
guid
analysi
approach
well
recent
compel
vaccin
efficaci
data
base
earli
success
advantag
conceptu
develop
like
vector
make
import
futur
contribut
vaccinolog
vaccin
plasmid
dna
gener
excit
earli
four
independ
group
simultan
report
plasmid
gene
deliveri
result
vivo
antigen
express
result
immun
respons
plasmidencod
antigen
stephan
johnson
laboratori
use
devic
call
gene
gun
shoot
gold
bead
coat
plasmid
encod
human
growth
hormon
mice
anim
gener
antibodi
growth
hormon
approach
group
also
attempt
har
power
plasmid
vaccin
purpos
present
work
session
cold
spring
harbor
vaccin
meet
fall
laboratori
margaret
liu
merck
harriet
robinson
univers
massachusett
vaccin
mice
intramuscularli
plasmid
express
influenza
antigen
demonstr
gener
antigenspecif
immun
addit
david
weiner
univers
pennsylvania
report
formul
plasmid
contain
either
hiv
envelop
tumor
antigen
capabl
stimul
cellular
humor
immun
respons
mice
case
tumor
antigen
formul
impact
tumor
growth
novel
result
combin
simplic
eas
manufactur
spawn
research
dna
vaccin
plethora
viral
bacteri
parasit
cancer
target
time
dna
vaccin
platform
perceiv
scientif
commun
import
new
approach
conceptu
dna
multipl
advantag
tradit
live
attenu
kill
peptidebas
viral
vector
vaccin
exampl
dna
easi
manipul
combin
simplic
synthet
chemistri
bacteri
product
power
genom
allow
rapid
design
construct
multipl
potenti
vaccin
remov
entir
need
develop
vaccin
use
pathogenderiv
materi
addit
dna
vector
extrem
stabl
reduc
need
cold
chain
increas
product
shelf
life
therefor
eas
product
stabil
costeffect
platform
made
ideal
produc
vaccin
develop
world
dna
vector
immunogen
allow
repeat
administr
without
develop
immun
interfer
importantli
dna
vaccin
combin
appeal
live
replic
vaccin
induc
broad
cellular
humor
immun
respons
safeti
eas
manufactur
nonliv
nonspread
platform
dna
vaccin
nonrepl
elimin
risk
attenu
revers
host
dissemin
recipi
unintend
consequ
secondari
infect
transfer
unvaccin
popul
deliv
highrisk
group
includ
immunocompromis
subject
clinic
dna
vaccin
sever
dna
vaccin
licens
use
anim
includ
dog
melanoma
immunotherapi
porcin
recombin
growth
hormon
vaccin
prevent
rhabdoviru
diseas
fish
west
nile
viru
vaccin
hors
promis
outcom
yet
translat
human
success
preclin
model
dna
vaccin
led
clinic
studi
human
initi
earli
goal
human
studi
evalu
safeti
toler
immun
potenc
platform
divers
dna
vaccin
varieti
prophylact
therapeut
applic
studi
includ
influenza
cancer
antigen
hepat
b
malaria
other
although
initi
dna
vaccin
studi
human
demonstr
excel
toler
safeti
immun
respons
elicit
much
weaker
expect
base
preclin
data
concern
abil
technolog
stimul
robust
immun
respons
led
develop
primeboost
strategi
sought
take
advantag
properti
dna
well
recombin
viral
vector
combin
result
focus
immun
transgen
see
highli
attenu
live
recombin
poxvirus
includ
nyvac
modifi
vaccinia
ankara
mva
alvac
canarypoxbas
vector
recombin
adenovir
platform
great
interest
although
viral
platform
induc
strong
antigenspecif
cellular
respons
preclin
model
preexist
poxviru
adenoviru
immun
diminish
immun
respons
induc
immun
recombin
vaccin
vector
limit
potenc
vector
multidos
regimen
furthermor
issu
regard
preexist
immun
also
possibl
problemat
discuss
earli
dna
approach
induc
small
focus
immun
respons
could
expand
subsequ
boost
recombin
vector
encod
antigen
dna
vaccin
prime
boost
strategi
provid
robust
immun
respons
strategi
first
suggest
studi
murin
model
malaria
dna
prime
follow
mva
nyvac
boost
consist
specif
preerythrocyt
antigen
plasmodium
berghei
induc
higher
tcell
respons
either
platform
deliv
alon
schneider
cowork
use
malaria
vaccin
report
prime
dna
boost
mva
vector
encod
antigen
led
enhanc
immun
greater
protect
efficaci
achiev
either
vaccin
prepar
alon
find
quickli
extend
mani
dna
recombin
vector
combin
import
shiv
simianhuman
immunodefici
viru
siv
simian
immunodefici
viru
model
vaccin
studi
use
dna
prime
follow
recombin
mva
boost
report
induc
cellmedi
immun
respons
improv
magnitud
nonhuman
primat
result
decreas
viremia
viral
challeng
accordingli
heterologousdnaprimefollowedbyviralvectorboost
immun
becam
popular
present
simpl
avail
option
improv
immun
respons
two
differ
vaccin
platform
result
robust
level
vaccinespecif
cellular
humor
immun
earli
clinic
evalu
heterolog
primeboost
vaccin
mcconkey
colleagu
illustr
benefit
studi
malaria
antigen
vaccin
test
vaccin
plasmid
antigen
cassett
encod
provid
unparallel
safeti
profil
past
decad
half
studi
constraint
dna
vaccin
product
develop
repeatus
manufactur
facil
thu
provid
enorm
save
product
develop
manufactur
mechan
surround
gener
antigenspecif
immun
genebas
vaccin
import
understand
antigen
sequenc
interest
design
target
particular
antigen
set
antigen
pathogen
tumor
antigen
potenti
subject
addit
modif
describ
insert
mammalian
express
plasmid
vector
use
human
vector
often
share
common
featur
includ
highcopynumb
origin
replic
enhanc
product
human
cytomegaloviru
immediateearli
promot
drive
vivo
express
rna
polyadenyl
sequenc
deriv
bovin
growth
hormon
creat
synthet
facilit
ribosom
function
plasmid
growth
select
sequenc
limit
kanamycin
bacteri
gene
nonantibiot
select
sequenc
monitor
express
plasmid
interest
product
plasmid
vaccin
deliv
skin
intraderm
inject
intramuscularli
one
sever
deliveri
method
insid
cytoplasm
cell
plasmid
enter
nucleu
transfect
cell
eg
myocyt
keratinocyt
local
resid
antigenpres
cell
apc
plasmidencod
sequenc
drive
host
cell
transcript
produc
foreign
antigen
vivo
hostsynthes
antigen
becom
subject
immun
surveil
context
mhc
class
class
ii
molecul
vaccin
host
specif
differ
dna
vaccin
infect
pathogen
vaccin
intend
prevent
dna
vaccin
antigen
deliveri
remain
local
plasmid
transfect
cell
littl
spread
antigen
express
region
bodi
plasmid
repres
focus
antigen
epitop
multipl
antigen
pathogen
entir
pathogen
capabl
dissemin
exact
detail
dna
vaccineinduc
immun
remain
subject
debat
im
inject
dna
vaccin
shown
induc
tcell
respons
limit
antibodi
product
im
inject
myocyt
like
transfect
dendrit
cell
present
transfect
muscl
effici
crosspres
antigen
activ
mhc
class
irestrict
cell
altern
apc
muscl
could
directli
transfect
express
antigen
via
mhc
class
pathway
activ
ctl
contrast
intraderm
id
administr
report
result
robust
humor
respons
consist
immunoglobulin
ig
g
antibodi
product
dermi
rich
apc
langerhan
dendrit
cell
id
vaccin
could
result
apc
transfect
antigen
secret
either
mhc
class
mhc
class
ii
present
apc
also
constantli
sampl
environ
endocytosi
result
uptak
secret
antigen
predomin
express
mhc
class
ii
cell
thought
plasmidencod
dna
trigger
immun
activ
stimul
innat
immun
sensor
includ
pamp
pathogenassoci
molecular
pattern
sting
stimul
interferon
gene
tankbind
kinas
pathway
activ
apc
express
chemokin
cytokin
enhanc
immun
cell
traffick
inflamm
gou
dna
primeboost
immun
elicit
immun
respons
greater
breadth
could
achiev
prime
boost
vector
fig
specif
studi
howev
provid
unexpect
lessposit
result
focus
phase
ii
studi
evalu
regimen
dna
prime
follow
boost
prevent
infect
reduc
viral
load
studi
particip
becam
natur
infect
vaccin
studi
design
earlier
studi
entitl
step
test
vector
encod
gag
pol
nef
antigen
hiv
step
trial
end
earli
futil
possibl
concern
person
vaccin
arm
acquir
hiv
infect
often
control
arm
new
trial
specif
design
avoid
potenti
risk
observ
step
studi
inclus
env
antigen
studi
part
vaccin
howev
trial
also
end
earli
futil
support
conclus
primeboost
approach
vaccin
platform
effect
specul
may
best
genet
vaccin
platform
hiv
strong
immun
cell
activ
may
work
vaccin
hiv
field
challeng
outcom
studi
shift
nonhuman
adenovir
vector
chimpanze
adenovir
vector
overal
prime
boost
strategi
continu
central
role
mani
vaccin
effort
target
divers
difficult
pathogen
illustr
mani
challeng
remain
major
interest
improv
immun
potenc
approach
mani
approach
taken
improv
immun
respons
induc
dna
vaccin
platform
tabl
start
reengin
plasmid
vector
better
deliv
express
antigen
vivo
includ
optim
promot
region
transcript
element
enhanc
antigen
express
level
improv
leader
sequenc
optim
plasmid
backbon
develop
improv
gene
sequenc
inclus
molecular
adjuv
formul
immun
modul
develop
varieti
nextgener
deliveri
approach
mani
area
review
highlight
detail
dna
technolog
highli
malleabl
muchimprov
dna
vaccin
immun
profil
describ
major
area
improv
plasmid
construct
design
includ
optim
promot
enhanc
element
polyadenyl
incorpor
novel
leader
sequenc
vector
design
antibiot
resist
select
sequenc
origin
replic
choic
product
effici
slimmer
backbon
design
delet
extran
dna
sequenc
may
contribut
improv
platform
perform
import
consider
increas
plasmiddriven
immun
potenc
involv
sequenc
optim
bacteri
rna
rich
au
sequenc
wherea
mammalian
dna
rich
gc
therefor
pool
transfer
rna
need
translat
human
cell
favor
sequenc
enrich
gc
redund
codon
usag
uniqu
transcript
differ
exist
bacteria
divers
virus
parasit
even
host
tumor
antigen
may
benefit
attent
genet
design
dna
sequenc
codonoptim
favor
transfer
rna
pool
avail
human
cell
allow
encod
messeng
rna
mrna
effici
translat
import
modif
increas
immun
potenc
rna
optim
chang
made
rna
sequenc
affect
amino
acid
sequenc
preerythrocyt
malaria
antigen
thrombospondinrel
adhes
protein
trap
follow
id
deliveri
recombin
modifi
mva
contain
trap
antigen
well
dnamva
combin
safe
induc
cellular
immun
respons
provid
partial
protect
irradiatedsporozoit
malaria
challeng
human
studi
geovax
biotechnolog
compani
use
hiv
antigen
cassett
show
dna
prime
follow
mva
boost
attract
combin
vaccin
modal
author
studi
dna
recombin
mva
hiv
antigen
vaccin
encod
gag
proteas
revers
transcriptas
nativ
membranebound
trimer
form
envelop
env
vaccin
antigen
report
dna
prime
follow
recombin
poxvir
boost
result
superior
tcell
immun
poxvir
vaccin
alon
followup
studi
investig
compar
data
hiv
env
protein
vaccin
protocol
protein
vaccin
administ
three
time
group
versu
second
group
group
receiv
four
administr
immun
hiv
poxvir
vector
follow
two
administr
hiv
protein
vaccin
versu
group
group
receiv
three
administr
immun
hiv
envencod
plasmid
vaccin
follow
boost
protein
twice
studi
report
signific
antibodi
respons
differ
three
arm
group
exhibit
lowest
neutral
antibodi
titer
high
level
bind
antibodi
respons
group
exhibit
high
neutral
titer
antibodi
group
interest
dna
primeprotein
boost
group
group
exhibit
highest
level
broadli
neutral
titer
observ
suggest
uniqu
benefit
dna
prime
context
protein
boost
nation
institut
health
nih
vaccin
research
center
report
sever
phase
trial
goal
develop
dna
prime
follow
recombin
adenoviru
serotyp
vector
boost
protocol
hiv
studi
vector
system
plasmid
adenoviru
serotyp
contain
similar
insert
vaccin
consist
fourconstruct
mixtur
plasmid
encod
subtyp
b
gagpolnef
fusion
protein
three
modifi
env
construct
subtyp
b
c
plasmid
dose
mg
studi
appear
similar
adenovir
vector
deliv
particl
unit
pu
volum
deltoid
singl
immun
primeboost
studi
observ
platform
capabl
induc
immun
respons
standalon
platform
platform
combin
dna
prime
administ
three
time
follow
boost
improv
immunogen
observ
sequenti
administr
result
higher
magnitud
envbias
tcell
respons
greater
antibodi
bind
titer
measur
enzymelink
immunosorb
assay
addit
possibl
advantag
heterolog
primeboost
regimen
induct
respons
differ
induc
repeat
dose
either
vaccin
modal
specif
report
cox
colleagu
show
cellular
respons
hiv
vaccin
express
gag
pol
nef
heterolog
regimen
induc
greater
gagspecif
tcell
respons
induc
homolog
regimen
human
furthermor
studi
schneider
cowork
robinson
colleagu
heterolog
dnapoxviru
primeboost
immun
strategi
found
tcell
respons
gener
heterolog
dnapoxviru
strategi
produc
immun
respons
time
higher
either
platform
given
separ
togeth
studi
establish
heteroloa
major
advantag
dna
platform
abil
rapidli
custom
vaccin
antigen
high
precis
address
specif
vaccin
design
limit
exampl
divers
hiv
env
sequenc
reach
greater
within
subtyp
greater
clade
similar
divers
issu
plagu
influenza
hepat
c
viru
malaria
vaccin
develop
among
other
therefor
vaccin
singl
viral
sequenc
unlik
drive
divers
respons
necessari
crossprotect
varieti
sequenc
circul
popul
approach
overcom
limit
combin
comput
predict
immunogen
design
synthet
chemistri
gener
vaccin
antigen
improv
natur
import
approach
includ
consensu
antigen
ancestor
gene
centeroftre
design
mosaic
antigen
epitop
string
approach
approach
seek
focu
immun
respons
induc
synthet
gene
cassett
final
vaccin
antigen
exampl
sequenc
rich
gc
like
form
secondari
structur
slow
translat
lower
vivo
protein
product
rna
optim
also
involv
remov
intern
cisact
motif
tata
box
repeat
sequenc
caus
instabl
cryptic
splice
site
unwant
ribosom
bind
site
combin
gene
optim
strategi
dramat
posit
effect
protein
express
vaccin
immunogen
recent
studi
west
nile
viru
vaccin
dna
use
improv
promot
induc
relev
antibodi
respons
trial
particip
studi
extend
find
report
trial
sever
acut
respiratori
syndrom
sar
ebola
plasmid
vaccin
result
low
posit
serolog
induc
vaccin
howev
low
tcell
respons
suggest
improv
still
import
platform
stand
alon
anoth
cytokin
gene
interleukin
il
also
receiv
great
deal
attent
dna
vaccin
adjuv
strong
thelper
cell
type
adjuv
expand
tcell
immun
includ
tcell
function
mous
model
increas
tcell
lysi
target
cell
use
dna
vaccin
nonhuman
primat
nhp
along
plasmid
encod
demonstr
increas
cellular
respons
correspond
control
viremia
improv
clinic
outcom
chimer
shiv
viru
nhp
challeng
viru
consist
siv
core
antigen
well
env
antigen
design
abil
plasmid
vector
increas
respons
dna
vaccin
current
studi
human
adjuv
effect
plasmid
codeliv
appear
significantli
enhanc
immun
respons
expand
tcell
respons
induc
vaccin
addit
tcell
growth
expans
factor
administ
hiv
antigen
dna
vaccin
show
posit
result
mous
macaqu
model
system
move
human
test
studi
person
compar
hiv
dna
vaccin
alon
hiv
dna
vaccin
given
either
vaccin
day
later
group
receiv
adjuv
day
later
exhibit
improv
enzymelink
immunosorb
spot
elispot
result
compar
either
group
studi
dna
vaccin
siv
model
use
checkpoint
inhibitor
ig
adjuv
report
studi
show
adjuv
group
show
superior
tcell
respons
dna
alon
dna
adjuv
group
furthermor
macaqu
challeng
highli
pathogen
monkey
viru
arm
seven
anim
show
sever
log
lower
peak
viremia
signific
control
infect
eas
specif
combin
adjuv
approach
dna
vaccin
arena
gener
enorm
amount
data
regard
vaccin
effect
import
cytokin
gene
costimulatori
molecul
chemokin
gene
heat
shock
antigen
immun
modul
molecul
like
area
continu
receiv
great
deal
attent
specif
epitop
region
nativ
antigen
antigen
predict
comput
analysi
conserv
invari
popul
diverg
virus
target
would
theori
preferenti
expand
desir
tand
bcell
respons
natur
would
drive
strategi
seek
maxim
crossreact
tcell
respons
induc
diverg
strain
pathogen
consensu
antigen
mosaic
antigen
epitop
string
current
studi
clinic
hepat
c
hepat
b
hiv
among
other
data
hiv
well
human
papillomaviru
hpv
discuss
dna
vaccin
approach
particularli
suit
deliv
geneencod
adjuv
modul
result
immun
respons
adjuv
deriv
host
gene
known
biolog
allow
unpreced
level
insight
adjuv
choic
unlik
tradit
adjuv
molecular
adjuv
deliv
plasmidencod
vector
part
along
antigenencod
vector
vaccin
molecular
adjuv
vector
transduc
cell
site
vaccin
secret
adjuv
molecul
local
thu
coordin
tempor
target
region
apc
drain
lymph
node
vaccin
antigen
granulocytemacrophag
colonystimul
factor
gmcsf
white
blood
cell
growth
factor
consider
adjuv
properti
one
first
gene
adjuv
clearli
demonstr
cytokin
plasmid
could
modul
dna
vaccineinduc
immun
mice
vaccin
rabi
viru
antigen
dna
addit
gmcsf
deliv
dna
increas
antibodi
product
tcell
respons
protect
lethal
challeng
accordingli
gmcsf
becam
wide
studi
dna
molecular
adjuv
examin
macaqu
human
clinic
studi
malaria
vaccin
howev
human
studi
adjuv
effect
clear
initi
anim
studi
remain
investig
part
new
deliveri
format
primeboost
protocol
biolist
jet
inject
jet
inject
involv
use
high
pressur
deliv
liquid
formul
dna
centimet
skin
surfac
major
limit
clinic
use
jet
inject
requir
larg
amount
dna
dna
degrad
highpressur
deliveri
howev
rel
simpl
techniqu
shown
improv
immun
respons
compar
im
inject
experiment
model
system
gene
gun
use
high
pressur
deliv
dnacoat
gold
nanoparticl
dermi
demonstr
high
transfect
effici
enhanc
antibodi
respons
sever
speci
includ
human
contrast
rel
littl
effect
improv
cellular
immun
electropor
ep
use
transfect
cell
vitro
decad
recent
use
vivo
increas
transfect
effici
dna
vaccin
ep
involv
appli
small
electr
field
across
site
inject
caus
temporari
membran
instabl
creat
electr
gradient
increas
plasmid
uptak
cell
field
techniqu
studi
decad
method
improv
deliveri
chemotherapi
drug
kill
specif
tumor
cell
sever
anim
speci
eg
dog
pig
cattl
nhp
deliv
gene
encod
varieti
hormon
cytokin
enzym
antigen
howev
condit
requir
ep
initi
consid
harsh
adopt
vaccin
strategi
yet
past
year
ep
technolog
develop
benign
deliveri
devic
comput
control
capabl
enhanc
deliveri
im
id
microneedl
transfect
approach
use
lower
voltag
toler
excit
develop
largeanim
model
deliveri
dna
vaccin
ep
led
increas
cellular
humor
immun
respons
rival
seen
viral
vector
newer
ep
approach
combin
dna
optim
approach
magnitud
immun
respons
gener
combin
dna
approach
increas
log
ep
technolog
also
tailor
particular
dna
vaccin
use
devic
control
current
voltag
time
set
combin
molecular
adjuv
also
look
highli
promis
deliveri
skin
muscl
mucos
report
data
multipl
primat
challeng
model
demonstr
much
improv
immunogen
efficaci
challeng
deliveri
plasmid
vaccin
initi
studi
dna
vaccin
clinic
demonstr
safeti
eas
product
immun
respons
adequ
initi
fear
regard
use
dna
vaccin
risk
integr
host
chromosom
subsequ
activ
oncogen
inactiv
tumor
suppressor
gene
howev
studi
demonstr
rate
dna
integr
vivo
actual
three
time
lower
rate
spontan
mutagenesi
addit
neg
effect
induct
autoimmun
transfer
antibiot
resist
marker
observ
renew
clinic
interest
approach
thousand
volunt
receiv
dna
vaccin
without
signific
vaccinerel
advers
event
report
fact
number
dna
vaccin
test
clinic
studi
compar
recombin
platform
increas
compris
trial
decemb
tabl
summar
sever
pivot
trial
dna
vaccin
one
area
serv
baromet
interest
experiment
platform
hiv
vaccin
trial
seven
particularli
basi
earli
posit
effect
report
clinic
dna
vaccin
deliv
without
benefit
viral
vector
coat
facilit
host
cell
attach
entri
suffer
intrins
limit
transfect
effici
compound
lack
replic
spread
potenti
therefor
major
area
research
focus
improv
dna
entri
target
cell
vivo
extent
efficaci
dna
vaccin
human
improv
increas
dosag
plasmid
deliv
earli
studi
human
use
dose
mg
less
newer
studi
use
dose
mg
increas
consist
frequenc
antibodi
product
formul
dose
high
mg
togeth
cytokin
express
vector
electropor
stimul
increas
tcell
respons
promis
approach
formul
includ
novel
transfect
reagent
major
focu
earli
studi
addit
physic
deliveri
becom
import
area
research
import
area
dna
deliveri
formul
dna
biodegrad
polymer
microparticl
see
review
well
contain
liposom
microparticleand
liposomebas
dna
vaccin
deliveri
system
studi
util
deliveri
enhanc
immunogen
sever
differ
host
antigen
vaccin
platform
small
anim
nhp
human
cytomegaloviru
cmv
influenza
dna
vaccin
compound
dual
role
facilit
plasmid
entri
cell
well
provid
adjuv
effect
polyethyleneimin
aminefunction
polymethacryl
cation
poli
ester
poloxam
polyvinylpyrrolidon
polym
addit
exampl
molecul
enhanc
dna
vaccin
immun
potenc
specif
system
poloxam
demonstr
improv
immun
potenc
preclin
model
simian
hiv
vaccin
addit
ongo
studi
show
liposom
vehicl
improv
dna
vaccineinduc
immun
respons
studi
liposom
gener
support
improv
still
modest
impact
antibodi
respons
lesser
impact
tcell
respons
liposom
structur
versatil
regard
result
vesicl
surfac
charg
cation
anion
liposom
made
size
lipid
content
codeliveri
adjuv
offer
abil
custom
specif
dna
applic
formul
dna
vaccin
polyamin
gel
nanoparticl
also
report
increas
uptak
plasmid
vector
increas
antigen
express
vivo
although
increas
research
area
well
studi
liposom
polym
approach
clinic
develop
trajectori
howev
alon
none
formul
appear
capabl
induc
immun
respons
dna
platform
rival
respons
induc
viral
vector
anoth
major
area
product
research
combin
dna
vaccin
physic
deliveri
method
physic
forc
plasmid
dna
cell
well
increas
number
transfect
cell
express
level
improv
improv
immun
respons
report
physic
deliveri
devic
gene
gun
elev
cervic
sampl
examin
women
clear
diseas
import
studi
optim
dna
vaccin
deliv
ep
addit
set
extend
find
addit
target
expand
applic
dna
platform
report
first
efficaci
data
clear
preced
discuss
improv
technolog
drive
field
see
tabl
progress
clinic
trial
close
watch
present
excit
pictur
next
year
variou
dna
approach
come
fruition
sever
dna
vaccin
licens
use
anim
product
licens
veterinari
use
includ
dog
melanoma
immunotherapi
porcin
therapi
porcin
recombin
growth
hormon
vaccin
prevent
rhabdoviru
diseas
fish
west
nile
viru
vaccin
hors
base
success
field
trial
dna
vaccin
import
safeti
record
technolog
anim
health
human
grow
databas
regard
consist
immun
respons
clinic
first
efficaci
data
report
human
report
success
licensur
veterinari
product
suggest
dna
vaccin
well
posit
becom
import
platform
continu
vaccin
immun
therapeut
develop
applic
nucleic
acid
encod
gene
nucleic
acid
vaccin
deliv
vivo
add
anoth
novel
approach
vaccineimmunotherapi
pipelin
use
plasmid
dna
vivo
antigen
product
mrna
deliv
encod
antigen
first
report
decad
ago
initi
dna
vaccin
took
center
stage
eas
product
stabil
problem
immunogen
soon
appreci
howev
rnabas
approach
reemerg
import
genet
vaccin
platform
rnabas
vaccin
approach
allow
infinit
boost
subject
neutral
host
immun
respons
even
previous
seroposit
individu
rna
vaccin
produc
custom
vivo
process
host
natur
fold
modifi
endogen
host
cell
system
similar
dna
vaccin
approach
antigen
produc
vivo
present
endogen
apc
stimul
tcell
respons
mimick
immun
respons
induc
live
infect
mixtur
rna
also
test
howev
similar
poor
immunogen
seen
dna
vaccin
earli
studi
use
rna
vaccin
also
plagu
low
immunogen
small
anim
well
manufactur
issu
result
low
product
yield
product
instabl
last
decad
rna
vaccin
improv
ex
vivo
transfect
studi
rna
immun
transfect
patientderiv
dendrit
cell
show
induct
immun
vivo
base
data
interest
cancer
immun
therapi
use
patientderiv
cell
modifi
transfect
either
mrna
deriv
cancer
cell
antigenspecif
synthes
mrna
focu
immun
respons
approach
test
pancreat
cancer
neuroblastoma
melanoma
colorect
cancer
lung
cancer
prostat
cancer
among
other
earli
studi
well
toler
addit
rnabas
approach
investig
deliveri
chimer
tcell
receptor
function
target
tumor
antigen
clinic
trial
sponsor
hiv
vaccin
trial
network
hvtn
evalu
dna
vaccin
elicit
immun
respons
either
alon
combin
multipl
viral
vector
boost
addit
new
studi
epdeliv
dna
alon
build
data
observ
hvtn
ep
dna
primeboost
strategi
develop
altern
approach
use
dna
prime
stimul
tcell
bcell
respons
follow
recombin
proteinboost
gener
morepot
antibodi
respons
dna
vaccin
also
studi
nonprimeboost
set
use
enhanc
physic
deliveri
exampl
hvtn
protocol
multiplecodon
genet
optim
dna
plu
plasmid
adjuv
deliv
ep
healthi
volunt
studi
report
induct
tcell
immun
studi
volunt
fact
threeimmun
protocol
induc
overal
tcell
respons
high
respons
previous
report
dna
prime
follow
poxvir
adenovir
boost
consist
five
immun
furthermor
induc
cell
still
detect
month
final
immun
first
studi
show
combin
ep
dramat
improv
tcell
respons
human
phase
studi
multioptim
synthet
consensu
deliv
ep
treatment
earli
hpv
diseas
recent
conduct
women
precancer
cervic
diseas
particip
vaccin
synthet
dna
encod
two
differ
hpv
oncogen
two
differ
oncogen
hpv
strain
type
week
week
week
three
dose
group
mg
mg
mg
plasmid
vaccin
studi
subject
evalu
induct
antibodi
well
ctl
contrast
prior
dna
vaccin
studi
women
studi
seroconvert
irrespect
dose
group
greater
second
dose
vaccin
antibodi
persist
least
month
final
immun
cellular
respons
demonstr
women
elispot
women
cytotox
assay
highdos
group
six
six
women
exhibit
kill
capac
target
base
encourag
data
phase
iib
studi
conduct
women
cervic
diseas
test
schedul
phase
studi
use
highest
dose
vaccin
primari
end
point
regress
diseas
secondari
end
point
regress
diseas
well
viral
clearanc
studi
report
studi
particip
regress
cervic
diseas
complet
clear
hpv
infect
p
similar
phase
studi
close
women
seroconvert
vaccin
antigen
greater
exhibit
strong
tcell
respons
furthermor
cell
rna
approach
conceptu
advantag
simpl
focus
immunogen
requir
nuclear
local
gener
express
replic
vector
selfamplifi
vector
expand
mrna
copi
provid
replic
machineri
alphavirus
maxim
express
newer
stabil
mrna
approach
exhibit
longer
halflif
compar
earliergener
mrna
vaccin
advanc
improv
deliveri
express
furthermor
rna
approach
strongli
stimul
host
innat
defens
system
part
activ
tolllik
receptor
tolllik
receptor
pathway
innat
activ
may
advantag
immun
prime
need
investig
overal
even
though
rna
field
catch
genet
vaccin
platform
next
gener
rna
vaccin
present
interest
opportun
standalon
platform
part
primeboost
protocol
among
viral
vector
studi
recombin
adenovir
vector
demonstr
immunogen
protect
immun
varieti
anim
model
vector
genet
modifi
deliv
express
specif
recombin
gene
product
unabl
grow
thu
replicationdefect
like
dna
vaccin
vector
transduc
cell
synthes
nativ
gene
product
appear
quit
potent
abil
induc
helper
specif
ctl
immun
major
clinic
vector
deriv
although
human
serotyp
six
subfamili
f
known
deriv
c
subfamili
common
beststudi
serotyp
howev
rel
high
preval
immun
human
popul
may
pose
limit
use
vector
preexist
immun
may
inhibit
respons
vaccin
immun
altern
serotyp
chimer
vector
develop
circumv
attract
immun
follow
success
varieti
preclin
anim
model
human
trial
phase
phase
ii
respect
anim
model
replicationdefect
adenoviru
elicit
potent
immun
respons
protect
ebolaviru
administ
either
alon
singl
inject
primeboost
combin
see
fig
primeboost
approach
induc
potent
durabl
immun
desir
prevent
vaccin
routin
use
wherea
singl
vaccin
induc
rapid
respons
suffici
immedi
protect
see
fig
approach
may
use
contain
acut
outbreak
ebola
infect
could
applic
pathogen
addit
vaccin
dna
boost
combin
directli
ex
vivo
approach
prefer
difficulti
rna
product
storag
among
difficulti
result
technolog
advanc
direct
inject
rna
vaccin
purpos
grow
import
reemerg
result
separ
advanc
field
rna
vaccin
one
advanc
abil
stabil
mrna
product
second
exist
potent
selfamplifi
rna
vector
base
alphaviru
platform
recent
studi
use
synthet
mrna
encod
influenza
antigen
optim
rna
gc
content
complex
protamin
mice
ferret
vaccin
formul
seroconvert
influenza
antigen
protect
influenza
challeng
singl
immun
formul
also
immunogen
anim
larg
pig
fulli
protect
influenza
challeng
pig
diseas
attenu
mrna
vaccin
test
human
focu
therapi
cancer
particularli
prostat
cancer
prostat
cancer
mrna
vaccin
contain
selfadjuv
mrna
encod
antigen
relev
prostat
diseas
includ
prostat
specif
antigen
prostat
stem
cell
antigen
prostat
specif
membran
antigen
six
transmembran
epitheli
antigen
prostat
evalu
immunogen
safeti
patient
advanc
castrationresist
prostat
cancer
mrnabas
vaccin
contain
free
protaminecomplex
mrna
support
stabil
deliveri
mrna
mice
vaccin
immunogen
suggest
vaccin
drove
innat
immun
stimul
mediat
part
via
tolllik
receptor
activ
clinic
studi
mrna
vaccin
administ
five
id
inject
recommend
dose
result
show
immun
respons
could
detect
least
one
vaccin
antigen
evalu
patient
patient
respond
one
vaccin
antigen
treatmentrel
advers
event
experienc
patient
includ
injectionsit
erythema
injectionsit
reaction
fatigu
pyrexia
chill
influenzalik
ill
although
reaction
consid
mild
natur
addit
safeti
studi
need
outcom
result
interest
immun
respond
show
trend
toward
increas
surviv
compar
nonimmun
respond
also
trend
better
clinic
outcom
base
induct
antigen
respons
patient
respond
three
antigen
better
outcom
respond
one
two
antigen
antibodi
respons
induc
vaccin
robust
tcell
respons
four
patient
show
increas
titer
test
vaccin
antigen
addit
studi
mrna
vaccin
area
import
follow
addit
area
import
rna
vaccin
field
reemerg
alphaviru
system
nonvir
rna
vaccin
deliveri
platform
exampl
studi
report
novarti
describ
selfamplifi
rna
technolog
approach
alphaviru
gene
encod
rna
replic
machineri
along
recombin
viral
target
antigen
synthes
laboratori
user
technolog
vaccin
mice
respiratori
syncyti
viru
f
protein
report
rapid
induct
potent
antibodi
respons
group
also
report
respons
nhp
studi
hiv
immunogen
selfamplifi
hiv
vaccin
induc
cell
measur
elispot
antibodi
respons
boost
adjuv
hiv
env
antigen
overal
data
clearli
illustr
platform
induc
immun
respons
mrna
vaccin
import
monitor
selfamplifi
vaccin
enter
clinic
evalu
altern
approach
evas
immun
includ
engin
vector
evad
domin
immun
respons
varieti
chimer
fiber
hexon
protein
describ
maintain
immunogen
evad
neutral
antibodi
fiber
use
hexon
chimera
appear
target
major
neutral
antibodi
respons
anoth
approach
antivector
immun
involv
develop
novel
vector
altern
serotyp
develop
vector
investig
evalu
rad
vector
lowseropreval
human
adenovirus
well
nhp
recombin
ad
vector
human
serotyp
well
describ
seropreval
ad
serotyp
suggest
subfamili
well
adenovirus
subfamili
includ
uncommon
human
thu
may
offer
advantag
vector
novel
vector
base
develop
preclin
studi
suggest
resist
immun
mice
altern
vector
show
lesspot
antibodi
respons
seen
also
appear
region
differ
seroposit
divers
rare
serotyp
rad
vector
exampl
although
b
serotyp
shown
promis
earli
clinic
trial
seropreval
low
north
america
seroposit
virus
approach
part
africa
complic
develop
regulatori
issu
vector
addit
replicationincompet
ad
vector
attenu
replicationcompet
vector
use
vaccin
vector
prevent
adenovir
mediat
diseas
militari
high
incid
diseas
among
recruit
live
vaccin
appear
well
toler
highli
effect
serotyp
also
develop
recombin
vector
platformsfor
exampl
hiv
vaccin
offer
potenti
altern
serotyp
use
oral
deliv
immun
stimulu
gut
mucosa
may
potenti
desir
effect
protect
viral
challeng
final
recombin
ad
vector
develop
altern
speci
includ
sheep
pig
cow
macaqu
chimpanze
particular
chimp
adenovir
vector
appear
gain
traction
clinic
evalu
specif
ebola
vaccin
supersed
new
chimp
adenovir
vaccin
chimpanzeederiv
replicationdefect
adenoviru
chad
vaccin
induc
uniform
protect
acut
lethal
ebolaviru
challeng
macaqu
howev
protect
short
live
boost
mva
ebola
vaccin
much
durabl
protect
lethal
ebolaviru
challeng
gener
human
studi
vaccin
induc
antibodi
respons
detect
vaccin
recipi
highest
dose
group
studi
vaccin
person
respond
elispot
assay
overal
data
encourag
surprisingli
preexist
neutral
antibodi
observ
chimp
adenovir
vector
subsaharan
africa
suggest
level
chimp
adenovirus
relat
virus
cross
human
popul
frequenc
find
consequ
beyond
hiv
vaccin
viral
vaccin
develop
nih
among
import
new
vaccin
candid
studi
context
recent
ebola
outbreak
west
africa
impact
preexist
immun
vaccin
other
develop
requir
addit
investig
conclus
immunogen
rad
vector
prompt
develop
candid
vaccin
varieti
infecti
diseas
vector
well
toler
highli
immunogen
moder
dose
concern
confer
partial
protect
rhesu
macaqu
multipl
hiv
isol
includ
replicationdefect
adenoviru
also
use
varieti
addit
anim
model
infecti
diseas
includ
plagu
anthrax
influenza
malaria
phase
phase
ii
clinic
studi
replicationdefect
adenovir
vector
conduct
sever
group
step
trial
clinic
efficaci
studi
vector
encod
gag
pol
nef
gene
evalu
effect
vaccineinduc
tcell
respons
control
viral
load
although
vaccin
immunogen
reduct
hiv
acquisit
longterm
control
postinfect
viremia
analys
reveal
person
specif
human
lymphocyt
antigen
type
well
develop
tcell
respons
certain
gag
nef
hiv
epitop
select
virus
contain
vaccin
epitop
vivo
also
unexpect
associ
infect
vaccin
recipi
uncircumcis
immun
vaccin
rate
hiv
infect
first
month
immun
regimen
appear
higher
subgroup
although
result
remain
controversi
clinic
util
dna
boost
vaccin
discuss
primeboost
section
trial
similar
merck
step
studi
also
end
earli
futil
result
support
improv
vector
approach
must
consid
improv
outcom
clinic
could
vector
issu
inclus
env
antigen
impact
posit
efficaci
trial
serolog
issu
associ
vector
well
controversi
regard
whether
increas
risk
hiv
infect
driven
interest
adenovir
vector
despit
abil
induc
potent
sustain
immun
respons
varieti
infecti
pathogen
concern
remain
preexist
immun
may
compromis
efficaci
certain
region
africa
seropreval
greater
high
degre
neutral
antibodi
limit
use
vector
although
cellular
humor
immun
respons
contribut
immun
like
neutral
antibodi
play
major
role
suppress
immunogen
seen
human
preexist
immun
shown
reduc
immunogen
ad
vaccin
mice
rhesu
monkey
potenti
human
clear
preexist
immun
human
complet
block
vaccin
immunogen
sever
strategi
develop
overcom
potenti
problem
rad
immun
novel
method
deliv
exist
recombin
ad
vector
explor
exampl
possibl
administr
higher
dose
recombin
vector
may
overcom
immun
although
strategi
may
limit
increas
toxic
dose
escal
ad
boost
dna
prime
may
potenti
reduc
immunosuppress
effect
although
seen
describ
hvtn
studi
final
administr
vector
mucos
rout
may
help
circumv
problem
howev
safeti
approach
particularli
intranas
deliveri
yet
determin
addit
sever
investig
explor
possibl
coat
particl
chemic
polyethylen
glycol
may
block
access
antibodi
viral
surfac
demonstr
reduct
frequenc
acquisit
hiv
infect
among
vaccin
heterosexu
men
women
compar
placebo
recipi
studi
repres
landmark
trial
provid
proof
concept
vaccin
could
prevent
infect
although
degre
efficaci
modest
although
attenu
poxvector
evalu
varieti
human
studi
clear
develop
vaccin
use
human
challeng
part
recombin
transgen
repres
small
minor
gene
product
express
otherwis
larg
vector
thu
certainti
immun
respons
focus
foreign
transgen
rather
gene
product
synthes
endogen
poxviru
addit
seen
rad
antivector
immun
remain
problemat
although
lesser
degre
canarypox
vector
poxviru
vector
show
thermost
abil
incorpor
larg
foreign
transgen
lack
persist
genom
integr
demonstr
success
smallpox
erad
howev
difficulti
manufactur
viru
high
yield
primari
cef
well
antigen
complex
reactogen
poor
immunogen
possibl
impact
effect
multipl
immun
regimen
poxvir
vaccin
test
human
malaria
challeng
model
vaccin
express
polyprotein
insert
consist
string
six
preerythrocyt
antigen
design
plasmodium
falciparum
follow
safeti
assess
singl
dose
volunt
receiv
heterolog
primeboost
vaccin
regim
involv
two
differ
poxviru
malaria
subunit
vaccin
contain
insert
mvapp
follow
immun
subject
underw
malaria
sporozoit
challeng
vaccin
safe
howev
tcell
elispot
respons
low
vaccin
efficaci
observ
novel
mva
vaccin
express
antigen
mycobacterium
tuberculosi
evalu
placebocontrol
phase
iib
trial
south
africa
infant
infant
previous
receiv
bacil
bcg
vaccin
random
receiv
either
placebo
intraderm
follow
immun
respons
protect
tuberculosi
although
vaccin
safe
immunogen
modest
efficaci
tuberculosi
infect
diseas
studi
malaria
tuberculosi
suggest
much
potent
immun
respons
need
impact
two
infect
thu
primeboost
strategi
pursu
addit
studi
infecti
diseas
arena
poxvir
vector
import
tool
multipl
cancer
immun
therapi
protocol
target
divers
tumor
type
studi
cell
induc
howev
poxvir
vector
appear
induc
modest
antibodi
respons
first
posit
efficaci
outcom
report
phase
iib
studi
use
recombin
poxvir
vector
prostvacvf
candid
anticanc
immunotherapi
therapi
prostat
cancer
origin
champion
nation
cancer
institut
develop
men
asymptomat
minim
symptomat
metastat
castrationresist
prostat
cancer
therapi
consist
prime
vaccinia
recombin
poxvir
vector
follow
five
monthli
immun
fowlpox
vector
vector
contain
ident
gene
insert
insert
includ
gene
sequenc
encod
modifi
immun
stimulatori
prostatespecif
antigen
cassett
along
addit
gene
cassett
three
human
immunostimulatori
molecul
known
tricom
leukocyt
functionassoci
intercellular
adhes
clinic
trial
treatment
gener
clear
antiprostatespecif
antigen
ctl
respons
vaccine
almost
antibodi
respons
preexist
immun
gener
number
new
approach
ad
vector
novel
deliveri
vector
molecularli
engin
altern
ad
serotyp
speci
provid
number
option
clinic
studi
varieti
infecti
diseas
well
cancer
immun
therapi
set
efficaci
vaccinia
viru
smallpox
repres
one
best
exampl
impact
vaccin
infecti
diseas
howev
safeti
issu
use
vaccinia
strain
smallpox
substanti
number
altern
vaccinia
viru
strain
develop
immun
vehicl
summar
box
attenu
vaccinia
virus
also
use
deliveri
vector
gene
product
specif
pathogen
smallpox
one
two
major
attenu
strain
poxviru
mva
develop
repeat
passag
ankara
vaccinia
strain
primari
chicken
embryo
fibroblast
cef
safer
altern
vaccin
smallpox
result
multipl
genet
chang
enabl
viru
replic
effici
varieti
nonavian
cell
type
second
altern
attenu
strain
new
york
vaccinia
strain
nyvac
develop
genet
modif
includ
delet
open
read
frame
associ
virul
host
rang
copenhagen
strain
nyvac
like
mva
attenu
anim
model
show
favor
safeti
immunogen
anim
human
nyvac
block
earli
stage
replic
although
abl
replic
product
african
green
monkey
kidney
cell
primari
cef
alvac
deriv
plaquepurifi
viru
isol
exist
canarypox
strain
canapox
abl
express
insert
transgen
immunogen
anim
earli
clinic
trial
addit
avipox
vector
includ
fowlpox
canarypox
vector
evalu
alon
primeboost
combin
varieti
infecti
diseas
cancer
model
see
review
gener
poxvirus
notabl
larg
genom
size
abil
express
recombin
gene
without
effect
replic
capac
polyval
recombin
use
immun
experiment
anim
prove
use
varieti
infecti
diseas
model
includ
rabi
measl
siv
canin
distemp
respiratori
syncyti
viru
malaria
influenza
addit
vector
studi
varieti
hiv
challeng
model
anim
human
studi
also
conduct
vaccinia
viru
alphaviru
modifi
express
heterolog
viral
gene
vaccin
infecti
diseas
target
includ
hiv
west
nile
viru
filovirus
cmv
pathogen
although
yet
clinic
interest
data
gener
nhp
challeng
model
novel
recombin
replic
simian
cmv
vector
rhcmvsiv
engin
contain
siv
antigen
env
gag
pol
vprvpx
four
separ
rhcmv
vector
concept
cmv
infect
potent
tcell
memori
drive
infect
therefor
recombin
antigen
express
vector
may
repres
novel
ctlinduc
vaccin
platform
illustr
exampl
anim
vaccin
twice
interv
rhcmvsiv
vector
rest
day
subject
repeat
lowdos
pathogen
sivmac
challeng
time
vaccin
challeng
anim
exhibit
close
complet
control
siv
challeng
surprisingli
tcell
respons
respons
impress
control
rather
appear
tcell
kill
redirect
context
mhc
ii
molecul
import
issu
develop
fieldreadi
vaccin
protocol
understand
protect
observ
specif
anim
understand
role
observ
class
ii
kill
relev
human
develop
similar
act
human
appropri
vector
studi
well
uniqu
differ
simian
cmv
human
cmv
vector
requir
investig
howev
interest
impact
difficult
siv
challeng
model
associ
control
immunebas
clearanc
import
avenu
research
control
hiv
chronic
infect
uniqu
vector
move
quickli
clinic
base
vesicular
stomat
platform
vsv
vsv
ebolaviru
vaccin
rvsvzebov
develop
public
health
agenc
canada
consist
recombin
replicationcompet
vsv
engin
express
surfac
glycoprotein
zair
strain
ebolaviru
fig
preclin
test
mice
nhp
demonstr
im
inject
rvsvzebov
induc
neutral
antibodi
capabl
protect
anim
challeng
lethal
dose
ebolaviru
phase
clinic
trial
studi
safeti
vaccin
report
vaccin
rvsvzebov
dose
rang
plaqu
form
unit
pfu
result
seriou
advers
event
report
side
effect
mild
fever
joint
pain
vesicular
dermat
vaccin
importantli
vaccin
result
transient
system
infect
gener
antibodi
ebolaviru
capabl
neutral
viru
vitro
describ
fulli
chapter
vaccin
deploy
current
outbreak
phase
iii
studi
design
use
ring
vaccin
strategi
singl
immun
protocol
excitingli
preliminari
result
phase
iii
clinic
trial
rvsvzebov
guinea
reveal
vaccin
effect
protect
close
contact
ebolaviru
patient
becom
infect
vaccin
administ
immedi
oppos
deliv
week
follow
patient
diagnosi
base
encourag
preliminari
data
world
health
organ
approv
continu
trial
elimin
postexposur
vaccin
arm
studi
test
need
qualifi
quantifi
antiebolaviru
immun
respons
gener
vaccine
determin
longev
protect
evalu
protect
gener
differ
strain
ebolaviru
nonetheless
data
impress
import
context
ebola
pandem
outbreak
vsv
ebola
exampl
press
servic
recombin
platform
result
urgenc
seriou
ctl
shown
abil
lyse
tumor
target
random
placebocontrol
doubleblind
phase
ii
clinic
trial
prostvacvf
increas
overal
surviv
patient
metastat
castrationresist
prostat
cancer
month
translat
reduct
risk
death
bavarian
nordic
conjunct
nation
cancer
institut
current
test
prostvac
without
gmcsf
adjuv
global
doubleblind
random
phase
iii
efficaci
trial
dub
prospect
interest
clinic
evalu
immun
therapeut
vaccin
context
checkpoint
inhibitor
therapi
well
improv
poxvir
immunogen
remain
import
adenoassoci
virus
aav
defin
initi
helper
virus
facilit
propag
wildtyp
adenoviru
cell
cultur
contrast
larg
genom
size
rad
vaccinia
vector
aav
genom
size
much
limit
size
insert
size
approxim
kb
like
replicationdefect
virus
particl
produc
packag
line
provid
complementari
structur
protein
made
constitut
cell
rather
viru
varieti
serotyp
defin
hiv
vaccin
express
evalu
phase
human
studi
poor
immunogen
result
altern
serotyp
includ
current
develop
may
assess
alon
primeboost
combin
efficaci
human
entir
uniqu
use
vector
also
describ
recent
recombin
adenoassoci
viru
vector
studi
platform
deliv
recombin
antibodi
gene
direct
vivo
product
antibodi
strategi
vector
immun
prophylaxi
allow
previous
identifi
rare
neutral
antibodi
engin
recombin
adenoassoci
viru
vector
upon
infect
result
vivo
antibodi
product
protect
antibodi
vector
immun
prophylaxi
also
allow
product
protect
antibodi
vivo
achiev
vaccin
sever
studi
demonstr
effect
deliveri
strategi
protect
nhp
siv
human
mice
hiv
mice
ferret
influenza
first
vector
immun
prophylaxi
approach
reach
clinic
inhibit
hiv
infect
similar
approach
describ
use
dna
vector
deliv
ep
dna
monoclon
antibodi
deliveri
approach
show
vivo
product
broadli
neutral
hiv
antibodi
well
antibodi
protect
dengu
challeng
collect
vector
immun
prophylaxi
relat
platform
clearli
excit
even
though
earli
mani
hurdl
overcom
illustr
gene
vector
revolution
way
think
tradit
vaccin
protect
infecti
diseas
alphavirus
negativestrand
rna
virus
modifi
express
foreign
recombin
gene
without
produc
pathogen
infect
prototyp
includ
venezuelan
equin
enceph
viru
sindbi
viru
semliki
forest
viru
replicationdefect
herp
simplex
viru
hsv
produc
use
packag
cell
line
similar
describ
replicationdefect
aav
alphaviru
vector
vaccin
develop
deliv
foreign
gene
potenti
immunogen
also
vector
hsv
includ
vesicular
stomat
viru
dengu
viru
type
yellow
fever
deploy
sinc
million
dose
administ
origin
develop
max
theiler
passag
singl
dose
vaccin
confer
lifelong
immun
pass
viru
use
basi
construct
new
chimer
tetraval
dengu
vaccin
cydtdv
chimerivax
consist
four
recombin
live
attenu
yellow
fever
viru
vaccin
backbon
surfac
env
premembran
gene
swap
one
four
serotyp
dengu
viru
see
fig
administ
vaccin
dose
consist
median
end
point
cell
cultur
infecti
dose
chimer
vector
vaccine
receiv
three
dose
vaccin
month
apart
phase
iib
clinic
trial
report
vaccin
effect
prevent
dengu
infect
vaccin
primarili
provid
protect
dengu
serotyp
offer
protect
serotyp
two
phase
iii
trial
dengu
endem
region
chimerivax
found
effect
prevent
dengu
viru
infect
includ
infect
dengu
serotyp
addit
test
research
need
determin
immun
correl
protect
vaccin
phase
iv
clinic
trial
like
need
licensur
monitor
continu
safeti
efficaci
feasibl
larg
scale
vaccin
chimerivax
import
fact
develop
vaccin
cost
billion
year
research
get
mileston
importantli
chimerivax
pois
one
first
exampl
success
licensur
recombin
genebas
vaccin
progress
recent
viral
vector
depend
develop
appropri
packag
cell
line
cell
substrat
viral
product
chang
regulatori
requir
allow
advanc
transform
cell
line
viru
product
prove
invalu
facilit
effort
recombin
adenovir
product
cell
line
support
product
clinicalgrad
progress
trial
hiv
studi
infecti
agent
ebolaviru
marburg
viru
tuberculosi
malaria
approv
cell
line
use
divers
vector
cell
line
use
develop
number
vaccin
includ
west
nile
influenza
virus
latter
case
propag
viru
subsequ
inactiv
administr
human
gener
replicationdefect
viral
vector
cell
line
allow
product
vector
use
human
vaccin
studi
virus
develop
vaccin
repres
member
summar
fig
includ
recombin
ad
poxvirus
measl
venezuelan
equin
enceph
viru
aav
progress
human
trial
develop
transform
cell
line
capabl
propag
contrast
previou
standard
avian
leukosisfre
primari
cef
repres
major
advanc
vaccin
product
technolog
cell
line
facilit
product
replicationdefect
viral
vector
stabli
transfect
cell
line
offer
potenti
improv
yield
stabl
product
capac
develop
line
taken
year
implement
regulatori
concern
regard
adventiti
agent
tumorigen
safeti
consist
consider
oversight
evalu
strength
limit
cell
substrat
continu
base
guidelin
creat
sever
year
ago
increas
number
line
becom
better
character
avail
lifethr
emerg
diseas
contrast
develop
chimer
attenu
yellow
fever
viru
vector
express
dengu
viral
antigen
stori
reminisc
develop
recombin
poxvir
vaccin
vector
live
attenu
strain
yellow
fever
vaccin
consid
one
world
effect
safest
vaccin
prm
e
gene
associ
form
complex
env
transport
correct
surfac
orient
allow
attach
e
antigen
allow
infect
replic
attenu
vaccin
e
antigen
contain
import
immun
target
protect
four
differ
dengu
viral
serotyp
den
differ
chimer
viru
construct
contain
serotyp
depict
schemat
bottom
figur
left
attenu
viral
particl
cartoon
b
varicella
zoster
virusebolaviru
vzvebov
figur
depict
genom
attenu
vzv
top
versu
genom
attenu
vzv
ebola
glycoprotein
insert
upstream
l
antigen
yellow
glycoprotein
vzv
orang
glycoprotein
ebola
strain
glycoprotein
switch
attenu
vesicular
stomat
backbon
construct
vzvebolaviru
vaccin
viral
particl
shown
schemat
construct
vaccin
gene
nativ
envelop
vzv
delet
glycoprotein
ebolaviru
zairekikwit
strain
insert
recombin
viral
genom
respons
pathogen
may
limit
consist
vivo
final
perhap
challeng
problem
abil
effect
gene
transfer
bacteria
mammalian
cell
like
special
transport
pathway
requir
success
implement
technolog
addit
improv
necessari
improv
efficaci
approach
remain
establish
clinic
substanti
work
anim
model
genet
vaccin
efficaci
recent
report
success
human
studi
guidanc
rather
sever
failur
brought
question
potenti
technolog
howev
statu
rapidli
chang
oldest
recombin
vector
platform
clinic
evalu
close
decad
sever
trial
use
poxviru
technolog
studi
efficaci
trial
includ
canarypox
mva
nyvac
evalu
variou
phase
iii
human
studi
product
technolog
poxvirus
well
research
goodmanufacturingpractic
procedur
amplif
virus
follow
protocol
similar
develop
vaccinia
viru
path
toward
clinic
studi
appear
rel
straightforward
past
decad
efficaci
data
elus
recent
posit
news
thai
trail
canarypox
vector
engin
carri
hiv
antigen
patient
boost
antigen
provid
possibl
glimps
efficaci
primeboost
platform
studi
approxim
protect
infect
report
subsequ
prostavac
immun
therapi
efficaci
trial
use
two
differ
poxvir
backbon
primeboost
fashion
demonstr
overal
increas
surviv
patient
metastat
castrationresist
prostat
cancer
month
import
result
support
potenti
impact
vector
target
futur
also
import
rememb
studi
recombin
mva
technolog
given
rise
potenti
safer
nextgener
vaccin
smallpox
similarli
dna
vaccin
undergon
phase
test
target
divers
collect
infecti
diseas
includ
ebolaviru
west
nile
viru
sar
coronaviru
mer
zika
influenza
viru
well
cancer
studi
proofofconcept
studi
virus
perform
first
anim
model
either
dna
primeboost
combin
use
newer
synthet
ep
system
studi
impress
protect
demonstr
anim
base
find
sever
phase
trial
complet
ebola
sar
west
nile
viru
diseas
target
case
influenza
nake
dna
dna
adjuv
gold
microparticl
biolist
advanc
clinic
test
particular
interest
develop
primeboost
strategi
stimul
product
broadli
neutral
antibodi
influenza
virus
demonstr
initi
mice
ferret
monkey
phase
studi
test
concept
human
reveal
even
singl
inject
dna
vaccin
prime
effect
tradit
vaccin
boost
viru
regimen
also
show
broadli
neutral
antistem
antibodi
elicit
vaccin
human
phase
iib
efficaci
trial
test
synthet
dna
deliv
ep
cervic
diseas
report
women
vaccin
arm
regress
diseas
cure
underli
infect
provid
first
efficaci
outcom
dna
vaccin
field
like
addit
studi
build
potent
approach
mani
infecti
agent
replic
mucos
membran
transit
gastrointestin
tract
primari
infect
abil
elicit
effect
immun
respons
site
desir
varieti
bacteria
abl
replic
mucos
site
natur
infect
propos
attenu
microorgan
modif
facilit
deliveri
antigen
might
allow
develop
improv
vaccin
protect
pathogen
enter
mucosa
develop
live
bacteri
vector
therefor
focus
abil
induc
mucos
iga
respons
cytolyt
tcell
respons
mucos
site
synthesi
protein
mammalian
cell
deliv
bacteri
vector
potenti
induc
cellular
immun
goal
mani
genebas
viral
nonvir
vaccin
approach
review
detail
elsewher
summar
briefli
among
live
bacteri
vector
use
antigen
deliveri
mucos
pathogen
attenu
includ
strain
listeria
monocytogen
salmonella
vibrio
cholera
shigella
mycobacteria
bovi
yersinia
enterocolitica
bacillu
anthraci
addit
commens
strain
streptococcu
gordonii
lactobacilli
staphylococci
use
induct
humor
cellular
respons
genebas
vaccin
l
monocytogen
particular
focu
research
gramposit
intracellular
pathogen
studi
model
understand
class
mhcrestrict
immun
respons
respons
normal
seen
bacteri
protein
coexpress
antigen
microorgan
use
special
system
introduc
protein
cell
facilit
process
present
mhc
class
differ
mutat
use
develop
attenu
strain
retain
abil
deliv
antigen
similarli
salmonella
bacteri
strain
intracellular
pathogen
becom
restrict
endosom
compart
eukaryot
cell
resist
lysi
varieti
mutat
introduc
salmonella
gener
sever
differ
live
vaccin
carrier
vaccin
prototyp
undergon
develop
vaccin
deliveri
among
bacteri
carrier
bovi
bacil
wide
use
bacteri
vaccin
exampl
organ
use
express
hiv
antigen
instanc
express
mammalian
gene
requir
modif
codon
consist
host
cell
type
improv
immunogen
present
howev
abil
microorgan
induc
cellular
immun
level
similar
adenovir
poxvir
vector
human
still
investig
area
intens
interest
use
live
bacteri
vector
deliveri
dna
vaccin
instanc
aim
bacteria
deliv
plasmid
dna
cytoplasm
infect
cell
organ
shigella
listeria
use
purpos
addit
attenu
salmonella
evalu
purpos
shown
promis
infecti
diseas
tumor
model
experiment
anim
although
use
bacteri
vector
attract
theori
difficult
reduc
method
practic
among
concern
possibl
revers
reactogen
potenti
pathogen
bacteria
wildtyp
form
stabil
recombin
bacteria
possibl
preexist
immun
exposur
natur
pathogen
may
limit
infect
varieti
host
genet
factor
modul
immun
respons
induc
bacteri
carrier
variabl
innat
immun
endem
region
impact
prostavac
extend
life
cancer
patient
abil
vgx
regress
clear
women
neoplast
cervic
diseas
serv
major
mileston
gene
base
vaccin
technolog
efficaci
outcom
come
fruition
last
year
suggest
specif
gene
base
platform
appear
come
age
preced
set
studi
provid
hope
addit
genebas
vaccin
becom
avail
human
use
may
contribut
develop
protect
immun
varieti
challeng
infecti
diseas
well
provid
new
therapi
cancer
refer
chapter
avail
expertconsultcom
import
studi
previous
discuss
dna
vaccin
approv
veterinari
use
includ
dna
vaccin
west
nile
viru
hors
dna
vaccin
infecti
hematopoiet
necrosi
viru
protect
farmrais
fish
addit
vaccin
develop
viral
hemorrhag
septicemia
viru
farm
salmon
studi
singl
inject
microgram
amount
dna
induc
rapid
longlast
immun
protect
among
mani
research
earli
clinic
accomplish
efficaci
data
report
multipl
genebas
studi
refresh
chang
protect
report
rvsvzebov
vaccin
studi
prevent
ebola
transmiss
west
africa
efficaci
tetraval
chimerivax
lower
hospit
improv
outcom
dengu
